A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma
OBJECTIVES:
- Determine the response rate to rebeccamycin analogue in children with relapsed or
refractory neuroblastoma.
- Determine the toxicity of this drug in these patients.
- Identify and establish in vitro biologic correlates of clinical responses and toxicity
of this drug in these patients.
OUTLINE: Patients receive rebeccamycin analogue IV over 1 hour once on days 1-5. Treatment
repeats every 3 weeks for at least 2 courses in the absence of disease progression or
unacceptable toxicity.
PROJECTED ACCRUAL: This study will accrue up to 30 patients within 1.5 years.
Interventional
Primary Purpose: Treatment
Response (complete response, very good partial response, or partial response)
No
Tanya Trippett, MD
Study Chair
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
98-095
NCT00003737
January 1999
September 2006
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |